Payment overview · 2025
General Payments
$1,634.70
113 reported records · 21 companies
Healthcare provider profile · identity verified
Brad M Ginevan, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHEFFIELD, AL · NPI 1285732016
Verified facts
What the public records show
CMS Open Payments records show Brad M Ginevan, MD received $1,634.70 in general payments during 2025 across 113 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Relistor, Rexulti, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Linzess by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xyosted by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $351.72 | 21.5% | 18 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $255.01 | 15.6% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $217.64 | 13.3% | 29 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $135.88 | 8.3% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $129.40 | 7.9% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.75 | 4.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.03 | 4.0% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.83 | 3.5% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $46.15 | 2.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.06 | 2.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.32 | 2.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.69 | 2.3% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $31.48 | 1.9% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $29.25 | 1.8% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $29.24 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.63 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.82 | 1.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.81 | 0.9% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $14.13 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.06 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.80 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,634.70 | 113 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $213.52 | 19 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $179.88 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $170.95 | 24 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $169.05 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $167.09 | 23 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $154.29 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $135.88 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $91.62 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.60 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.75 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $75.75 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $57.83 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $46.15 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.06 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.49 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.32 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.56 | 4 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $31.48 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $29.24 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 102 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 195 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 162 | exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 47 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
110 | 29 |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
195 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
195 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
231 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
114 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
162 | 31 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
162 | 46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1854 | 246 |
| Gabapentin | Gabapentin | 1077 | 168 |
| Pantoprazole Sodium | Pantoprazole Sodium | 645 | 150 |
| Atorvastatin Calcium | Atorvastatin Calcium | 583 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 548 | 112 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 536 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 131 |
| Furosemide | Furosemide | 473 | 113 |
| Potassium Chloride | Potassium Chloride | 439 | 95 |
| Omeprazole | Omeprazole | 436 | 108 |
| Trazodone Hcl | Trazodone Hcl | 418 | 85 |
| Pregabalin | Pregabalin | 389 | 57 |
| Lisinopril | Lisinopril | 371 | 98 |
| Zolpidem Tartrate | Zolpidem Tartrate | 357 | 43 |
| Montelukast Sodium | Montelukast Sodium | 349 | 73 |
| Meloxicam | Meloxicam | 321 | 73 |
| Tramadol Hcl | Tramadol Hcl | 316 | 60 |
| Quetiapine Fumarate | Quetiapine Fumarate | 304 | 50 |
| Alprazolam | Alprazolam | 292 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 291 | 84 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 284 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 282 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 271 | 50 |
| Clonazepam | Clonazepam | 266 | 39 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 263 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 247 | 48 |
| Metformin Hcl | Metformin Hcl | 247 | 79 |
| Metformin Hcl Er | Metformin Hcl | 234 | 51 |
| Methocarbamol | Methocarbamol | 231 | 51 |
| Mounjaro | Tirzepatide | 231 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 63 |
| Bupropion Xl | Bupropion Hcl | 209 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 209 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 41 |
| Jardiance | Empagliflozin | 195 | 36 |
| Ibuprofen | Ibuprofen | 191 | 41 |
| Sertraline Hcl | Sertraline Hcl | 185 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 182 | 38 |
| Allopurinol | Allopurinol | 175 | 38 |
| Lorazepam | Lorazepam | 170 | 34 |
| Promethazine Hcl | Promethazine Hcl | 169 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 168 | 40 |
| Eliquis | Apixaban | 162 | 46 |
| Ozempic | Semaglutide | 162 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 159 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 155 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 149 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 144 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 38 |
| Buspirone Hcl | Buspirone Hcl | 140 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 133 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 28 |
| Ezetimibe | Ezetimibe | 129 | 25 |
| Celecoxib | Celecoxib | 127 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 123 | 34 |
| Topiramate | Topiramate | 123 | 25 |
| Temazepam | Temazepam | 121 | 18 |
| Losartan Potassium | Losartan Potassium | 118 | 32 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 116 | suppressed |
| Famotidine | Famotidine | 116 | 37 |
| Trulicity | Dulaglutide | 114 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 48 |
| Linzess | Linaclotide | 110 | 29 |
| Carvedilol | Carvedilol | 109 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 108 | 23 |
| Fenofibrate | Fenofibrate | 107 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 107 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 103 | 20 |
| Farxiga | Dapagliflozin Propanediol | 102 | 27 |
| Prednisone | Prednisone | 101 | 54 |
| Glimepiride | Glimepiride | 97 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 21 |
| Mirtazapine | Mirtazapine | 97 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 97 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 96 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 96 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 86 | 20 |
| Azithromycin | Azithromycin | 85 | 70 |
| Amitriptyline Hcl | Amitriptyline Hcl | 83 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 83 | 23 |
| Estradiol | Estradiol | 76 | 16 |
| Spironolactone | Spironolactone | 75 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 70 | 13 |
| Methylprednisolone | Methylprednisolone | 69 | 50 |
| Levetiracetam | Levetiracetam | 68 | 12 |
| Fluconazole | Fluconazole | 67 | 32 |
| Meclizine Hcl | Meclizine Hcl | 65 | 28 |
| Simvastatin | Simvastatin | 65 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | suppressed |
| Atenolol | Atenolol | 62 | 14 |
| Ondansetron Odt | Ondansetron | 62 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 14 |
| Mometasone Furoate | Mometasone Furoate | 60 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 35 |
| Eszopiclone | Eszopiclone | 54 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 39 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Baclofen | Baclofen | 52 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 52 | suppressed |
| Cefdinir | Cefdinir | 51 | 46 |
| Kerendia | Finerenone | 51 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 27 |
| Januvia | Sitagliptin Phosphate | 49 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | 17 |
| Clonidine Hcl | Clonidine Hcl | 47 | 20 |
| Propranolol Hcl | Propranolol Hcl | 47 | 14 |
| Relistor | Methylnaltrexone Bromide | 47 | 13 |
| Vascepa | Icosapent Ethyl | 47 | suppressed |
| Aripiprazole | Aripiprazole | 45 | 12 |
| Lamotrigine | Lamotrigine | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 43 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Sucralfate | Sucralfate | 43 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 32 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Naproxen | Naproxen | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Colchicine | Colchicine | 37 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 30 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 12 |
| Glipizide | Glipizide | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 27 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | 11 |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 13 |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Diazepam | Diazepam | 27 | 13 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | 13 |
| Nystatin | Nystatin | 26 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 11 |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Valsartan | Valsartan | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 20 |
| Primidone | Primidone | 21 | suppressed |
| Armodafinil | Armodafinil | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Niacin Er | Niacin | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Calcitriol | Calcitriol | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Xyosted | Testosterone Enanthate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,634.70 · 113 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, DALVANCE, FARXIGA, GEMTESA, JARDIANCE, JATENZO, JOURNAVX, Kerendia, Korlym, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, Quviviq, RELISTOR, REPATHA, REXULTI, Sunosi, TRINTELLIX, TRULANCE, TWIIST, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error